RALEIGH, N.C. — Salix Pharmaceuticals has signed an agreement with Cedars-Sinai Medical Center for wider use of two patents utilized in creation of a drug for treatment of irritable bowel syndrome.

Salix now has worldwide rights to market and sell licensed products related to rifaximin on a global basis. Salix markets the drug under the name Xifaxan and is seeking Food and Drug Administration approval for its use as an indicator of irritable bowel syndrome.

In exchange, Cedars-Sinai will receive a license fee and royalties.

Also on Wednesday, Salix said it was seeking additional marketing exclusivity time for its gastrointestinal drug Colazal.

Salix: www.salix.com